Advertisement

Cell-Penetrating Peptides as Carriers for Transepithelial Drug Delivery In Vitro

  • Stine Rønholt
  • Mie Kristensen
  • Hanne Mørck Nielsen
Part of the Methods in Molecular Biology book series (MIMB, volume 1324)

Abstract

There is a growing interest in the use of cell-penetrating peptides (CPPs) as carriers for transepithelial drug delivery. This chapter gives an introduction to and discussion of the commonly used production and characterization methods for CPP–cargo samples including high-throughput cell viability screening. Moreover, we describe methods for permeation and cell viability assessment in the Caco-2 cell culture model with and without implementation of biosimilar mucus. Last, a method to assess metabolic degradation in vitro is described.

Key words

Caco-2 Cell viability Cell-penetrating peptides as carriers High-throughput screening In vitro Mucus Metabolic degradation Permeability Transepithelial drug delivery 

Notes

Acknowledgements

María García-Díaz is acknowledged for supplying the protocols for the mucus preparation and the permeation study using Caco-2 cell monolayers supplemented with biosimilar mucus. The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no. 115363 resources which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007–2013) and EFPIA companies’ in kind contribution. Additionally, the work was financially supported by the Drug Research Academy (University of Copenhagen), The Danish Agency for Science, Technology & Innovation, and the Novo Nordisk Foundation Center for Protein Research.

References

  1. 1.
    Stewart KM, Horton KL, Kelley SO (2008) Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6:2242–2255CrossRefPubMedGoogle Scholar
  2. 2.
    Lindgren M, Rosenthal-Aizman K, Saar K, Eiríksdóttir E, Jiang Y, Sassian M, Ostlund P, Hällbrink M, Langel U (2006) Overcoming methotrexate resistance in breast cancer tumour cells by the use of a new cell-penetrating peptide. Biochem Pharmacol 71:416–425CrossRefPubMedGoogle Scholar
  3. 3.
    Margus H, Padari K, Pooga M (2012) Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery. Mol Ther 20:525–533PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Morris MC, Depollier J, Mery J, Heitz F, Divita G (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–1176CrossRefPubMedGoogle Scholar
  5. 5.
    Khafagy E-S, Kamei N, Nielsen EJB, Nishio R, Takeda-Morishita M (2013) One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats. Eur J Pharm Biopharm 85:736–743CrossRefGoogle Scholar
  6. 6.
    Khafagy E-S, Morishita M (2012) Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64:531–539CrossRefGoogle Scholar
  7. 7.
    Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K (2008) Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 132:21–25CrossRefPubMedGoogle Scholar
  8. 8.
    Liang JF, Yang VC (2005) Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem Biophys Res Commun 335:734–738CrossRefPubMedGoogle Scholar
  9. 9.
    Artursson P, Palm K, Luthman K (1996) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 22:67–84CrossRefGoogle Scholar
  10. 10.
    Boegh M, Baldursdóttir SG, Müllertz A, Nielsen HM (2014) Property profiling of biosimilar mucus in a novel mucus-containing in vitro model for assessment of intestinal drug absorption. Eur J Pharm Biopharm 87:227–235CrossRefPubMedGoogle Scholar
  11. 11.
    Boegh M, Baldursdottir SG, Nielsen MH, Müllertz A, Nielsen HM (2013) Development and rheological profiling of biosimilar mucus. Annu Trans Nord Rheol Soc 21:233–240Google Scholar
  12. 12.
    Hilgendorf C, Spahn-Langguth H, Regårdh CG, Lipka E, Amidon GL, Langguth P (2000) Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J Pharm Sci 89:63–75CrossRefPubMedGoogle Scholar
  13. 13.
    Hämäläinen MD, Frostell-Karlsson A (2004) Predicting the intestinal absorption potential of hits and leads. Drug Discov Today Technol 1:397–405CrossRefPubMedGoogle Scholar
  14. 14.
    Antunes F, Andrade F, Ferreira D, Nielsen HM, Sarmento B (2013) Models to predict intestinal absorption of therapeutic peptides and proteins. Curr Drug Metab 14:4–20CrossRefPubMedGoogle Scholar
  15. 15.
    Irvine JD, Takahashi L, Lockhardt K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin − Darby Canine Kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28–33CrossRefPubMedGoogle Scholar
  16. 16.
    Forbes B (2000) Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm Sci Technol Today 3:18–27CrossRefPubMedGoogle Scholar
  17. 17.
    Rupniak T, Rowlatt C, Lane EB, Steele JG, Trejdosiewicz LK, Laskiewicz B, Povey S, Hill BT (1985) Characteristics of four new human cell lines derived from squamous cell carcinomas of the head and neck. J Natl Cancer Inst 75:621–635PubMedGoogle Scholar
  18. 18.
    Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP (1996) Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24:634–642PubMedGoogle Scholar
  19. 19.
    Elmquist A, Langel U (2003) In vitro uptake and stability study of pVEC and its all-D analog. Biol Chem 384:387–393CrossRefPubMedGoogle Scholar
  20. 20.
    Nielsen EJB, Yoshida S, Kamei N, Iwamae R, Khafagy e-S, Olsen J, Rahbek UL, Pedersen BL, Takayama K, Takeda-Morishita M (2014) In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin. J Control Release 189:19–24CrossRefPubMedGoogle Scholar
  21. 21.
    Rennert R, Wespe C, Beck-Sickinger AG, Neundorf I (2006) Developing novel hCT derived cell-penetrating peptides with improved metabolic stability. Biochim Biophys Acta 1758:347–354CrossRefPubMedGoogle Scholar
  22. 22.
    Horne WS, Gellman SH (2008) Foldamers with heterogeneous backbones. Acc Chem Res 41:1399–1408PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Pantzar N, Lundin S, Wester L, Weström BR (1994) Bidirectional small-intestine permeability in the rat to some common marker molecules in vitro. Scan J Gastroenterol 8:703–709CrossRefGoogle Scholar
  24. 24.
    Kristensen M, Foged C, Berthelsen J, Nielsen HM (2013) Peptide-enhanced oral delivery of therapeutic peptides and proteins. J Drug Del Sci Tech 23:365–373CrossRefGoogle Scholar
  25. 25.
    Kasimova MR, Velázquez-Campoy A, Nielsen HM (2011) On the temperature dependence of complex formation between chitosan and proteins. Biomacromolecules 12:2534–2543CrossRefPubMedGoogle Scholar
  26. 26.
    Eirheim HU, Bundgaard C, Nielsen HM (2004) Evaluation of different toxicity assays applied to proliferating cells and to stratified epithelium in relation to permeability enhancement with glycocholate. Toxicil In Vitro 18:649–657CrossRefGoogle Scholar
  27. 27.
    Zhu X, Shan W, Zhang P, Jin Y, Guan S, Fan T, Yang Y, Zhou Z, Huang Y (2014) Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery. Mol Pharm 11:317–328CrossRefPubMedGoogle Scholar
  28. 28.
    Tréhin R, Nielsen HM, Jahnke H-G, Krauss U, Beck-Sickinger AG, Merkle HP (2004) Metabolic cleavage of cell-penetrating peptides in contact with epithelial models: human calcitonin (hCT)-derived peptides, Tat(47-57) and penetratin(43-58). Biochem J 382:945–956PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    Navabi N, McGuckin MA, Lindén SK (2013) Gastrointestinal cell lines form polarized epithelia with and adherent mucus layer when cultured in semi-wet interfaces with mechanical stimulation. PLoS One 8:e68761PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Tippin TK, Thakker DR (2008) Biorelevant refinement of the Caco-2 cell culture model to assess efficacy of paracellular permeability enhancers. J Pharm Sci 97:1977–1993CrossRefPubMedGoogle Scholar
  31. 31.
    Briske-Anderson MJ, Finley JW, Newman SM (1997) The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc Soc for Exp Biol Med 214:248–257CrossRefGoogle Scholar
  32. 32.
    Hirose H, Takeuchi T, Osakada H, Pujals S, Katayama S, Nakase I, Kobayashi S, Haraguchi T, Futaki S (2012) Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol Ther 20:1–10CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Stine Rønholt
    • 1
  • Mie Kristensen
    • 1
  • Hanne Mørck Nielsen
    • 2
  1. 1.Department of Pharmacy, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  2. 2.Section for Biologics, Department of Pharmacy, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations